Core Viewpoint - 康泰医学 held an investor relations meeting on September 15, 2025, to discuss product development and market strategies, revealing significant insights into their operations and future plans [1] Group 1: Product Development - The "Embodied Motion Rehabilitation Intelligent Equipment" project, led by Hebei University of Technology in collaboration with Fudan University and Yanshan University, won the first prize in the 2024 Hebei Provincial Science and Technology Progress Award, indicating successful technology transfer into business applications [1] - The company is focusing on the development of mid-to-high-end products and medical devices to address product homogenization and meet changing market demands [1] - The company is actively working on the development of exoskeleton robot products and will disclose relevant information as per regulatory requirements [1] Group 2: Market Strategy - 康泰医学 is enhancing its domestic market presence through deep collaborations with leading e-commerce platforms to boost brand awareness and influence [1] - The company plans to expand its global market coverage by leveraging research and product advantages, targeting regions such as Southeast Asia, Africa, and South America, driven by the increasing demand for cost-effective medical devices due to global aging and home healthcare trends [1] Group 3: Financial Performance - The company's second-quarter profits were impacted by market conditions, seasonal sales, and increased R&D investments, prompting a focus on market promotion, product structure optimization, and cost control to enhance profitability [1] - Shareholder reductions were attributed to personal funding needs, with the company adhering to regulations and commitments while maintaining normal operations [1] Group 4: AI and Innovation - 康泰医学 is investing in AI technology, exploring its integration with medical devices, and focusing on innovations in patient monitoring through algorithm development, aiming to advance smart healthcare [1]

Group 1: Product Development and Innovation - The company has developed key technologies in "embodied motion rehabilitation intelligent equipment," which won the 2024 Hebei Provincial Science and Technology Progress Award [2] - Ongoing projects include medical endoscopes, in vitro diagnostic products, and dental consumables to meet changing market demands [3] - The company focuses on high-end products and has optimized existing products in ECG, blood pressure, and blood oxygen categories while actively developing new products [2] Group 2: Market Strategy and Expansion - The company is enhancing its domestic market presence through deep cooperation with leading e-commerce platforms to increase brand awareness [4] - Plans to expand into Southeast Asia, Africa, and South America are underway, targeting the growing demand for cost-effective medical devices in these regions [6] - The company aims to improve global market coverage and penetration through localized construction and cross-border e-commerce initiatives [6] Group 3: Financial Performance and Governance - The company's performance in the second quarter was not profitable, with profits primarily from the first quarter; management remains confident in future growth [7] - Shareholder reductions in holdings are attributed to personal financial needs and comply with legal regulations [7] - Recent changes in the supervisory board were part of normal governance optimization and did not involve any collective board incidents [4] Group 4: Technological Advancements - The company is actively investing in AI technology, focusing on integrating AI with medical devices and developing algorithms for patient monitoring [7] - Innovations include multi-mode temperature detection and pulse wave-based respiratory rate calculations, contributing to the advancement of smart healthcare [7]